Electronic Journal of General Medicine

• Hande KR. Principles and Pharmacology of Chemotherapy. In Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B (eds); Wintrobe’s Clinical Hematology, 11th Edition, Volume II, Part VII, Ch: 73, pp: 1945-1969, Lippincott Williams & Wilkins Co. Philadelphia 2003
• Eckhardt S. Molecular targeted therapy: a strategy of disillusions or optimism? J Lab Clin Med 2006;147:108-13
• Peggs K, Mackinnon S. Imatinib Mesylate--the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003;348:1048-50
• Roux C, Boisseau-Gersaud AM, SaintCyr I, Hekenon R, Quist D, Delaunay C. Lichenoid cutaneous reaction to imatinib. Ann Dermatol Venereol 2004;131:571-3
• Wetzler M, Byrd JC, Bloomfield CD. Acute and Chronic Myeloid Leukemia. In Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (eds). Harrison’s Principles of Internal Medicine. 16th Edition, Part: V, Ch: 96, pp: 631-641. McGRAW – HILL Co. New York 2005
• Foringer JR, Verani RR, Tjia VM, Finkel KW, Samuels JA, Guntupalli JS. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Ann Pharmacother 2005;39:2136-8
• Cross TJ, Bagot C, Portmann B, Wendon J, Gillett D. Imatinib mesylate as a cause of acute liver failure. Am J Hematol 2006;81:189-92
• De Arriba JJ, Nerín c, García E, GomezAldaraví L, Vila B. Severe hemolytic anemia and skin reaction in a patient treated with imatinib. Ann Oncol 2003; 14:962
• Scheinfeld N. Imatinib Mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib Mesylate. J Drugs Dermatol 2006;5:228- 31
• Hsiao LT, Chung HM, Lin JT, Chiou TJ, Liu JH, Fan FS, Wang WS, Yen CC, Chen PM. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol 2002; 117: 620-2
• Schaich M, Schakel K, Illmer T, Ehninger G, Bornhauser M. Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation. Ann Hematol 2003;82:303-4
• Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to Imatinib (STI-571) in Philadelphia chromosome positive leukemias: A prospective study of 54 patients. J Am Acad Dermatol 2003; 48: 201-6
• Prabhash K, Doval DC. Lichenoid eruption due to imatinib. Indian J Dermatol Venereol Leprol 2005;71:287-8
• Dalmau J, Peramiquel L, Puig L, Fernandez-Figueras MT, Roe E, Alomar A. Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect. Br J Dermatol 2006;154:1213-6
• Lim D, Muir J. Lichenoid eruption to STI 571. Am J Hematol 2002;70:179
• Ena P, Chiarolini F, Siddi GM, Cossu A. Oral lichenoid eruption secondary to imatinib (Glivec). J Dermatolog Treat 2004;15:253

Vancouver

Kiki I, Atasoy M, Gursan N, Gundogdu M, Erdem F, Ozdemir S. LICHENOID DRUG ERUPTION ASSOCIATED WITH IMATINIB MESYLATE: TWO CASES. EUR J GEN MED. 2007;4(1):50-3. https://doi.org/10.29333/ejgm/82431

APA

Kiki, I., Atasoy, M., Gursan, N., Gundogdu, M., Erdem, F., & Ozdemir, S. (2007). LICHENOID DRUG ERUPTION ASSOCIATED WITH IMATINIB MESYLATE: TWO CASES. European Journal of General Medicine, 4(1), 50-53. https://doi.org/10.29333/ejgm/82431

AMA

Kiki I, Atasoy M, Gursan N, Gundogdu M, Erdem F, Ozdemir S. LICHENOID DRUG ERUPTION ASSOCIATED WITH IMATINIB MESYLATE: TWO CASES. EUR J GEN MED. 2007;4(1), 50-53. https://doi.org/10.29333/ejgm/82431

Chicago

Kiki, Ilhami, Mustafa Atasoy, Nesrin Gursan, Mehmet Gundogdu, Fuat Erdem, and Sevki Ozdemir. "LICHENOID DRUG ERUPTION ASSOCIATED WITH IMATINIB MESYLATE: TWO CASES". European Journal of General Medicine 2007 4 no. 1 (2007): 50-53. https://doi.org/10.29333/ejgm/82431

Harvard

Kiki, I., Atasoy, M., Gursan, N., Gundogdu, M., Erdem, F., and Ozdemir, S. (2007). LICHENOID DRUG ERUPTION ASSOCIATED WITH IMATINIB MESYLATE: TWO CASES. European Journal of General Medicine, 4(1), pp. 50-53. https://doi.org/10.29333/ejgm/82431

MLA

Kiki, Ilhami et al. "LICHENOID DRUG ERUPTION ASSOCIATED WITH IMATINIB MESYLATE: TWO CASES". European Journal of General Medicine, vol. 4, no. 1, 2007, pp. 50-53. https://doi.org/10.29333/ejgm/82431